ABO mismatch increases transplant‐related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation

Abstract

Significantly more patients with ABO mismatch showed transplant-associated complications and died as a result of transplant-related causes.

Lack of effect of donor–recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation

“…[13][14][15][16][17][18][19][20][21]33,34 However, the relative ease of testing for such correlations, the well-known and highly prevalent phenomenon of publication bias, and the presence of a number of studies in the literature that have failed to confirm such correlations [22][23][24][25][26][27][28][29][30][31][32] led us to hypothesize that publication bias itself may be partly or wholly responsible for the appearance of such reports in the literature. To our knowledge, the current study is the only investigation of these issues in the BMT literature in which the authors have specified a single, precisely defined primary statistical end point before initiating the actual analysis, and used formal statistical adjustments to reduce the risk of reporting false-positive associations involving secondary end points.…”

“…[1][2][3][4][5][6][7][8][9][10][11][12] However, the literature contains strikingly disparate opinions regarding the potential effect of ABO mismatching on other important outcome parameters including the incidence of death, relapse, graft-versus-host disease (GVHD), and transplant-related-mortality. Specifically, various investigators have concluded that ABO mismatching increases, [13][14][15][16][17][18][19][20][21] does not affect, [22][23][24][25][26][27][28][29][30][31][32] or decreases, [33][34] the incidence of one or more of the latter events.…”

Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation

“…Since PBSC grafts contain appoximately one log more CD19 þ B lymphocytes compared with marrow, delayed massive immune hemolysis due to donor-derived alloantibodies after minor or bidirectional ABO-incompatible allogeneic PBSCT has recently been reported. 12,13,21,22 Moreover, Worel et al 23 reported that severe immune hemolysis after minor ABOincompatible allogeneic PBSCT occurred more frequently after nonmyeloablative than after myeloablative conditioning. They suggested that the use of other immunosuppressive agents than methotrexate (MTX) as GVHD prophylaxis, which inhibits proliferation of T-and Blymphocytes and antibody production, might induce more common immune hemolysis after nonmyeloablative PBSCT.…”

Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT

“…This is in contrast to previous ABO mismatch studies that noted increased duration and absolute number of RBC transfusions after MJ and BD mismatch and increased PLT transfusion requirements in MN mismatch. 3,7,22,48 PBSC and RIC have both been associated with increased severity of passenger lymphocyte syndrome in patients with MN ABO mismatch, thought secondary to increased numbers of immunocompetent CD3+ T cells and CD19+ B cells transplanted along with a PBSC graft. [49][50][51][52] .…”